S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
Simple Options Trading for Beginners retails on Amazon for $19.95 and has 4 out of 5 stars. It was written by a stock market trading veteran with over 44 years of experience. Because of a special promotion, this book is 100% FREE for you today.

NASDAQ:PACB - Pacific Biosciences of California Stock Price, Forecast & News

$4.98
-0.06 (-1.19 %)
(As of 01/20/2020 01:17 PM ET)
Today's Range
$4.91
Now: $4.98
$5.10
50-Day Range
$4.64
MA: $5.15
$5.58
52-Week Range
$4.37
Now: $4.98
$7.50
Volume1.92 million shs
Average Volume2.58 million shs
Market Capitalization$761.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$78.63 million
Book Value$0.76 per share

Profitability

Net Income$-102,560,000.00
Net Margins-139.22%

Miscellaneous

Employees401
Market Cap$761.74 million
Next Earnings Date2/10/2020 (Estimated)
OptionableOptionable

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $21.92 million for the quarter, compared to analysts' expectations of $28.02 million. Pacific Biosciences of California had a negative net margin of 139.22% and a negative return on equity of 136.85%. View Pacific Biosciences of California's Earnings History.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Pacific Biosciences of California.

What price target have analysts set for PACB?

3 Wall Street analysts have issued 12-month price objectives for Pacific Biosciences of California's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Pacific Biosciences of California's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 53.9% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.

What is the consensus analysts' recommendation for Pacific Biosciences of California?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.

What are Wall Street analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
  • 1. According to Zacks Investment Research, "Pacific Biosciences has been gaining ground in the MedTech space on strong Sequel performance. The company’s product revenues also shot up in recent times. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the termination of the formerly announced $1.20 billion-merger agreement. Per management, Illumina will be paying Pacific Biosciences a termination fee of $98 million. Expansion in gross margin in recent times is also a positive. On the flip side, significant rise in operating expenses remains concerning. The company’s loss per share remained flat year over year. The DNA sequencing market is fraught with competition. The stock has underperformed its industry in a year’s time and is overvalued at the moment." (1/7/2020)
  • 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019)

Has Pacific Biosciences of California been receiving favorable news coverage?

Media coverage about PACB stock has been trending positive this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Pacific Biosciences of California.

Are investors shorting Pacific Biosciences of California?

Pacific Biosciences of California saw a increase in short interest in December. As of December 31st, there was short interest totalling 20,380,000 shares, an increase of 7.5% from the December 15th total of 18,960,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is presently 9.7 days. Currently, 14.7% of the shares of the stock are short sold. View Pacific Biosciences of California's Current Options Chain.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), FireEye (FEYE), Novavax (NVAX), CenterPoint Energy (CNP), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Pfizer (PFE), Alkaline Water (WTER), Exelixis (EXEL) and Netflix (NFLX).

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
  • Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 51)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.04%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $4.98.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $761.74 million and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is http://www.pacb.com/.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel